Related references
Note: Only part of the references are listed.Comparative efficacy and safety of biologic agents in patients with active rheumatoid arthritis and inadequate response to tumor necrosis factor inhibitors: A Bayesian network meta-analysis of randomized controlled trials
Yoon-Kyoung Sung et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2022)
A tumor-specific pro-IL-12 activates preexisting cytotoxic T cells to control established tumors
Diyuan Xue et al.
SCIENCE IMMUNOLOGY (2022)
Dissecting the molecular control of immune cell accumulation in the inflamed joint
Catriona T. Prendergast et al.
JCI INSIGHT (2022)
Restoring the Balance between Pro-Inflammatory and Anti-Inflammatory Cytokines in the Treatment of Rheumatoid Arthritis: New Insights from Animal Models
Adrienn Markovics et al.
BIOMEDICINES (2022)
Exploiting protease activation for therapy
Chloe Bleuez et al.
DRUG DISCOVERY TODAY (2022)
ADG153, an Anti-CD47 Monoclonal Antibody Prodrug, Has Strong In Vivo Anti-Tumor Activity, Minimal RBC-Related and Antigen Sink Liabilities, and Extended Half Life in Comparison with Benchmark Clinical Antibodies of the Same IgG Subclass
Bin Cai et al.
BLOOD (2021)
The Uniqueness of Albumin as a Carrier in Nanodrug Delivery
Alessandra Spada et al.
MOLECULAR PHARMACEUTICS (2021)
A review on applications of abatacept in systemic rheumatic diseases
Min Liu et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2021)
Selective activation of pro-anti-IL-1β antibody enhances specificity for autoinflammatory disorder therapy
Wen-Wei Lin et al.
SCIENTIFIC REPORTS (2021)
A Tale of Two Immune Cells in Rheumatoid Arthritis: The Crosstalk Between Macrophages and T Cells in the Synovium
Jiajie Tu et al.
FRONTIERS IN IMMUNOLOGY (2021)
Probody Therapeutics: An Emerging Class of Therapies Designed to Enhance On-Target Effects with Reduced Off-Tumor Toxicity for Use in Immuno-Oncology
Karen A. Autio et al.
CLINICAL CANCER RESEARCH (2020)
The past, present and future perspectives of matrix metalloproteinase inhibitors
Kang A. Li et al.
PHARMACOLOGY & THERAPEUTICS (2020)
Abatacept in rheumatoid arthritis and the risk of cancer: a world observational post-marketing study
Sibylle de Germay et al.
RHEUMATOLOGY (2020)
Overproduced bone marrow neutrophils in collagen-induced arthritis are primed for NETosis: An ignored pathological cell involving inflammatory arthritis
Danyi Xu et al.
CELL PROLIFERATION (2020)
Up to 5-year retention of abatacept in Belgian patients with moderate-to-severe rheumatoid arthritis: a sub-analysis of the international, observational ACTION study
R. Westhovens et al.
RHEUMATOLOGY INTERNATIONAL (2020)
Ab locks for improving the selectivity and safety of antibody drugs
Wen-Wei Lin et al.
JOURNAL OF BIOMEDICAL SCIENCE (2020)
Post-transplant lymphoproliferative disorders, Epstein-Barr virus infection, and disease in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice
Upton D. Allen et al.
CLINICAL TRANSPLANTATION (2019)
Specific activation of pro-Infliximab enhances selectivity and safety of rheumatoid arthritis therapy
Yun-Chi Lu et al.
PLOS BIOLOGY (2019)
Development of an inflammatory tissue-selective chimeric TNF receptor
Chia-Jung Lee et al.
CYTOKINE (2019)
Comparative risk of malignancies and infections in patients with rheumatoid arthritis initiating abatacept versus other biologics: a multi-database real-world study
Teresa A. Simon et al.
ARTHRITIS RESEARCH & THERAPY (2019)
MMP3 is a reliable marker for disease activity, radiological monitoring, disease outcome predictability, and therapeutic response in rheumatoid arthritis
Aaron Lerner et al.
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY (2018)
Enriched Cd141(+) DCs in the joint are transcriptionally distinct, activated, and contribute to joint pathogenesis
Mary Canavan et al.
JCI INSIGHT (2018)
Bruton's tyrosine kinase inhibitor BMS-986142 in experimental models of rheumatoid arthritis enhances efficacy of agents representing clinical standard-of-care
Kathleen M. Gillooly et al.
PLOS ONE (2017)
In Situ Activation of Pituitary-Infiltrating T Lymphocytes in Autoimmune Hypophysitis
Han-Huei Lin et al.
SCIENTIFIC REPORTS (2017)
Selective antibody activation through protease-activated pro-antibodies that mask binding sites with inhibitory domains
I-Ju Chen et al.
SCIENTIFIC REPORTS (2017)
Effects of CTLA4-Ig on human monocytes
Toshihiro Tono et al.
INFLAMMATION AND REGENERATION (2017)
Matrix metalloproteinase-9 (MMP-9) as an activator of nanosystems for targeted drug delivery in pancreatic cancer
Barbara Gruenwald et al.
JOURNAL OF CONTROLLED RELEASE (2016)
Synovial fluid proteome in rheumatoid arthritis
Mitali Bhattacharjee et al.
CLINICAL PROTEOMICS (2016)
VpreB serves as an invariant surrogate antigen for selecting immunoglobulin antigen-binding sites
Mohamed Khass et al.
SCIENCE IMMUNOLOGY (2016)
Matrix metalloproteinases as biomarkers of disease: updates and new insights
Emanuela Galliera et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2015)
Matrix Metalloproteinases in Inflammatory Bowel Disease: An Update
Shane O'Sullivan et al.
MEDIATORS OF INFLAMMATION (2015)
Combinatorial proteomic analysis of intercellular signaling applied to the CD28 T-cell costimulatory receptor
Ruijun Tian et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Abatacept decreases disease activity in a absence of CD4+ T cells in a collagen-induced arthritis model
Diahann T. S. L. Jansen et al.
ARTHRITIS RESEARCH & THERAPY (2015)
The Efficacy of Abatacept in Reducing Synovial T Cell Activation by CD1c Myeloid Dendritic Cells Is Overruled by the Stimulatory Effects of T Cell-Activating Cytokines
F. M. Moret et al.
ARTHRITIS & RHEUMATOLOGY (2015)
Abatacept (CTLA-4IG) treatment reduces the migratory capacity of monocytes in patients with rheumatoid arthritis
M. Bonelli et al.
ARTHRITIS AND RHEUMATISM (2013)
Safety of Abatacept Administered Intravenously in Treatment of Rheumatoid Arthritis: Integrated Analyses of up to 8 Years of Treatment from the Abatacept Clinical Trial Program
Michael E. Weinblatt et al.
JOURNAL OF RHEUMATOLOGY (2013)
Tumor-Specific Activation of an EGFR-Targeting Probody Enhances Therapeutic Index
Luc R. Desnoyers et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Indoleamine 2,3 dioxygenase and metabolic control of immune responses
David H. Munn et al.
TRENDS IN IMMUNOLOGY (2013)
Intra-articular CD1c-expressing myeloid dendritic cells from rheumatoid arthritis patients express a unique set of T cell-attracting chemokines and spontaneously induce Th1, Th17 and Th2 cell activity
Frederique M. Moret et al.
ARTHRITIS RESEARCH & THERAPY (2013)
Brief Report: Amelioration of collagen-induced arthritis in mice by lentivirus-mediated silencing of microRNA-223
Yuan-Tsung Li et al.
ARTHRITIS AND RHEUMATISM (2012)
In Vivo Positron Emission Tomography Imaging of Protease Activity by Generation of a Hydrophobic Product from a Noninhibitory Protease Substrate
Chih-Hung Chuang et al.
CLINICAL CANCER RESEARCH (2012)
Site-specific targeting of antibody activity in vivo mediated by disease-associated proteases
Oran Erster et al.
JOURNAL OF CONTROLLED RELEASE (2012)
Rigid-body Ligand Recognition Drives Cytotoxic T-lymphocyte Antigen 4 (CTLA-4) Receptor Triggering
Chao Yu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
MECHANISMS OF DISEASE The Pathogenesis of Rheumatoid Arthritis
Iain B. McInnes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Expression levels and association of gelatinases MMP-2 and MMP-9 and collagenases MMP-1 and MMP-13 with VEGF in synovial fluid of patients with arthritis
Kyoung Soo Kim et al.
RHEUMATOLOGY INTERNATIONAL (2011)
Cleavage of IgGs by proteases associated with invasive diseases An evasion tactic against host immunity?
Randall J. Brezski et al.
MABS (2010)
A multiparameter approach to monitor disease activity in collagen-induced arthritis
Sylvie Seeuws et al.
ARTHRITIS RESEARCH & THERAPY (2010)
Blocking Effect of an Immuno-Suppressive Agent, Cynarin, on CD28 of T-Cell Receptor
Guo-Chung Dong et al.
PHARMACEUTICAL RESEARCH (2009)
Crucial role of the interleukin-6/interleukin-17 cytokine axis in the induction of arthritis by glucose-6-phosphate isomerase
Keiichi Iwanami et al.
ARTHRITIS AND RHEUMATISM (2008)
Collagen-induced arthritis
David D. Brand et al.
NATURE PROTOCOLS (2007)
Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition
MC Genovese et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
CD1a and CD1c activate intrathyroidal T cells during graves' disease and Hashimoto's thyroiditis
C Roura-Mir et al.
JOURNAL OF IMMUNOLOGY (2005)
Protein structure prediction and analysis using the Robetta server
DE Kim et al.
NUCLEIC ACIDS RESEARCH (2004)
CTLA-4-Ig regulates tryptophan catabolism in vivo
U Grohmann et al.
NATURE IMMUNOLOGY (2002)
Selective cleavage of human IgG by the matrix metalloproteinases, matrilysin and stromelysin
AJH Gearing et al.
IMMUNOLOGY LETTERS (2002)
T cell activation in rheumatoid synovium is B cell dependent
S Takemura et al.
JOURNAL OF IMMUNOLOGY (2001)
Structure of murine CTLA-4 and its role in modulating T cell responsiveness
DA Ostrov et al.
SCIENCE (2000)
Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis
Y Yoshihara et al.
ANNALS OF THE RHEUMATIC DISEASES (2000)